| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 632 | 2013 |
| Challenges to effective cancer control in China, India, and Russia PE Goss, K Strasser-Weippl, BL Lee-Bychkovsky, L Fan, J Li, ... The lancet oncology 15 (5), 489-538, 2014 | 561 | 2014 |
| Human selenoproteins at a glance S Gromer, JK Eubel, BL Lee, J Jacob Cellular and Molecular Life Sciences CMLS 62, 2414-2437, 2005 | 327 | 2005 |
| Breast cancer in Brazil: present status and future goals BL Lee, PER Liedke, CH Barrios, SD Simon, DM Finkelstein, PE Goss The lancet oncology 13 (3), e95-e102, 2012 | 234 | 2012 |
| Progress and remaining challenges for cancer control in Latin America and the Caribbean K Strasser-Weippl, Y Chavarri-Guerra, C Villarreal-Garza, BL Bychkovsky, ... The lancet oncology 16 (14), 1405-1438, 2015 | 199 | 2015 |
| Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer R Barroso-Sousa, TE Keenan, S Pernas, P Exman, E Jain, ... Clinical cancer research 26 (11), 2565-2572, 2020 | 147 | 2020 |
| Cervical cancer control in Latin America: A call to action BL Bychkovsky, ME Ferreyra, K Strasser‐Weippl, CI Herold, ... Cancer 122 (4), 502-514, 2016 | 64 | 2016 |
| Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate B Lee, H Bauer, J Melchers, T Ruppert, L Rattray, V Yardley, ... Journal of medicinal chemistry 48 (23), 7400-7410, 2005 | 53 | 2005 |
| Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward CH Barrios, G Werutsky, A Mohar, AS Ferrigno, BG Müller, BL Bychkovsky, ... The Lancet Oncology 22 (11), e474-e487, 2021 | 51 | 2021 |
| Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis M Debiasi, CA Polanczyk, P Ziegelmann, C Barrios, H Cao, JJ Dignam, ... Frontiers in Oncology 8, 156, 2018 | 36 | 2018 |
| Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often? BL Bychkovsky, NU Lin The Breast 31, 318-324, 2017 | 35 | 2017 |
| Older women’s experience with breast cancer treatment decisions MA Schonberg, RL Birdwell, BL Bychkovsky, L Hintz, V Fein-Zachary, ... Breast cancer research and treatment 145, 211-223, 2014 | 33 | 2014 |
| Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care—checking CHEK2 BL Bychkovsky, NB Agaoglu, C Horton, J Zhou, A Yussuf, P Hemyari, ... Jama Oncology 8 (11), 1598-1606, 2022 | 32 | 2022 |
| Genomic characterization of de novo metastatic breast cancer AC Garrido-Castro, LF Spurr, ME Hughes, YY Li, AD Cherniack, P Kumari, ... Clinical Cancer Research 27 (4), 1105-1118, 2021 | 29 | 2021 |
| Cancer pathology turnaround time at Queen Elizabeth Central Hospital, the largest referral center in Malawi for oncology patients LPL Masamba, PE Mtonga, L Kalilani Phiri, BL Bychkovsky Journal of global oncology 3 (6), 734-739, 2017 | 22 | 2017 |
| Compulsory licenses for cancer drugs: does circumventing patent rights improve access to oncology medications? CLFB Bognar, BL Bychkovsky, GL Lopes Jr Journal of global oncology 2 (5), 292-301, 2016 | 22 | 2016 |
| Denosumab and the current status of bone-modifying drugs in breast cancer BL Lee, MJ Higgins, PE Goss Acta Oncologica 51 (2), 157-167, 2012 | 21 | 2012 |
| Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen B Bychkovsky, A Laws, F Katlin, M Hans, M Knust Graichen, LE Pace, ... Breast Cancer Research and Treatment 193 (2), 417-427, 2022 | 12 | 2022 |
| Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics BL Bychkovsky, MT Lo, A Yussuf, C Horton, M Richardson, H LaDuca, ... Cancer 128 (6), 1275-1283, 2022 | 12 | 2022 |
| Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer P Tarantino, H Gupta, ME Hughes, J Files, S Strauss, G Kirkner, ... Nature communications 14 (1), 7496, 2023 | 11 | 2023 |
Nancy LinDana-Farber Cancer Institute在 partners.org 的电子邮件经过验证
